| Brian R. Whitney, Od Pc | |
|
66 W Harding Ave, Cedar City, UT 84720-2695 | |
| (435) 586-9949 | |
| (435) 865-0388 |
| Full Name | Brian R. Whitney, Od Pc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 66 W Harding Ave, Cedar City, Utah |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821273319 | NPI | - | NPPES |
| 59211566202001 | Other | UT | BLUE CROSS BLUE SHIELD |
| 529115662001 | Medicaid | UT | |
| P00314487 | Other | UT | MEDICARE RAILROAD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 1134229934 (Utah) | Primary |
| Provider Name | Brian R Whitney |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1861571234 PECOS PAC ID: 5799790291 Enrollment ID: I20060223000101 |
News Archive
Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the death of tumour cells derived from breast, lung and colon cancer, and prevents their growth. The importance of this new gene is that its use to fight cancer can reduce the potent drugs that are currently used, so that could mean more effective treatment for cancer.
Cholesterol, a naturally occurring compound at the lung surface, has been shown to have a clear effect on the properties of this nanoscale film that covers the inside of our lungs.
Now in its 11th year of providing a voice for people who have kidney disease and are passionate about writing, Renal Support Network announces the winners of its Annual Essay Contest.
Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase, being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia, ineligible for intensive remission induction therapy.
BioSante Pharmaceuticals, Inc. today announced positive GVAX AML Vaccine results and BioSante's receipt of Orphan Drug designation from the FDA's Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia. This Orphan Drug designation is the second GVAX cancer vaccine from BioSante to secure FDA orphan drug designation.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian R. Whitney, Od Pc Po Box 988, Cedar City, UT 84721-0988 Ph: (435) 586-9949 | Brian R. Whitney, Od Pc 66 W Harding Ave, Cedar City, UT 84720-2695 Ph: (435) 586-9949 |
News Archive
Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the death of tumour cells derived from breast, lung and colon cancer, and prevents their growth. The importance of this new gene is that its use to fight cancer can reduce the potent drugs that are currently used, so that could mean more effective treatment for cancer.
Cholesterol, a naturally occurring compound at the lung surface, has been shown to have a clear effect on the properties of this nanoscale film that covers the inside of our lungs.
Now in its 11th year of providing a voice for people who have kidney disease and are passionate about writing, Renal Support Network announces the winners of its Annual Essay Contest.
Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase, being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia, ineligible for intensive remission induction therapy.
BioSante Pharmaceuticals, Inc. today announced positive GVAX AML Vaccine results and BioSante's receipt of Orphan Drug designation from the FDA's Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia. This Orphan Drug designation is the second GVAX cancer vaccine from BioSante to secure FDA orphan drug designation.
› Verified 6 days ago
Dr. David Paul Eastman, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1333 N Main St, Cedar City, UT 84721 Phone: 435-586-9777 | |
Barry Jackson Od Optometrist Medicare: Not Enrolled in Medicare Practice Location: 51 E 400 N, Suite 4a, Cedar City, UT 84720 Phone: 435-586-1500 Fax: 435-865-0784 | |
Southern Utah Vision Care, Inc. Optometrist Medicare: Medicare Enrolled Practice Location: 1251 Northfield Rd, Suite 215, Cedar City, UT 84720 Phone: 435-865-9899 | |
Dr. Rory J. Christian, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1811 W Royal Hunte Dr Ste 1, Cedar City, UT 84720 Phone: 435-586-1131 Fax: 435-865-1121 | |
Edgar Fernando Judd, OD Optometrist Medicare: Medicare Enrolled Practice Location: 1251 Northfield Rd Ste 215, Cedar City, UT 84721 Phone: 435-865-9899 | |
Dr. Steven C Taggart, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1330 S Providence Center Dr, Cedar City, UT 84720 Phone: 435-865-2809 Fax: 435-865-2867 | |
Dr. Loy D Brown, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 51 E 400 N, #4a, Cedar City, UT 84721 Phone: 435-586-0700 Fax: 435-865-0784 |